Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae326 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Mor Miodovnik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms, Immunotherapy, Skin Ulcer. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cutaneous squamous cell carcinoma (cSCC) is characterized by a high tumor mutational burden due to solar damage and a favorable response to anti-PD-1 immunotherapy. Yet, we encounter tumors arising in areas with minimal sun exposure, such as cSCC that develops in chronically inflamed skin, also known as Marjolin’s Ulcer (MU). The response of MU-SCC to immunotherapy remains unknown.
Methods
We performed a retrospective analysis of patients diagnosed with cSCC and treated with cemiplimab or pembrolizumab in a single tertiary medical center. Patients lost to follow up were excluded.
Results
Of the 84 eligible patients, 9 (11%) had MU-SCC. Of these, 2 (22%) reached partial response (PR), and none reached complete response (CR). In contrast, of the 75 patients with solar damage-related cSCC, 40 had PR (53%), and 20 had CR (26%). The difference between the two subtypes was significant (P < .001). Interestingly, 3 patients with MU-SCC received a second-line chemo-immunotherapy and experienced a partial response that continued for 5 to 21 months. Patients with MU-SCC had a significantly shorter median time to progression (TTP) (1.6 vs 51.6 months, P < .001) and progression-free survival (PFS) (1.6 vs 15.4 months, P < .001). Overall survival (OS) was not significantly shorter (17.4 vs 36.7 months, P = .096). Multivariate analysis confirmed that MU-SCC is an independent risk factor for shorter TTP (HR 5.5, 95% CI 2.2-14.0, P < .001) and PFS (HR 3.5, 95% CI 1.5-8.1, P = .003).
Conclusions
This study suggests that immunotherapy is less beneficial in SCC-MU. More work is needed to verify our findings and explore other treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
ORCID-Profile: Mor Miodovnik, Yasmin Leshem
Zitieren
APA
Miodovnik, M., Dolev, Y., Buchen, R., Brezis, M. R., Nikolaevski-Berlin, A., Finkel, I., Wolf, I., Ospovat, I., Gutfeld, O., & Leshem, Y. (2025). Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy. The Oncologist. https://doi.org/10.1093/oncolo/oyae326
Vancouver
Miodovnik M, Dolev Y, Buchen R, Brezis MR, Nikolaevski-Berlin A, Finkel I, et al. Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy. The Oncologist. 2025. doi:10.1093/oncolo/oyae326
BibTeX
@article{Miodovnik2025,
author = {Miodovnik, Mor and Dolev, Yardenna and Buchen, Roni and Brezis, Miriam Rivka and Nikolaevski-Berlin, Alla and Finkel, Inbar and Wolf, Ido and Ospovat, Inna and Gutfeld, Orit and Leshem, Yasmin},
title = {Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae326}
}
EUVIMED